FDA
-
-
-
-
-
-
-
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
-
-
-
-
-
-
-
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurt
-
-
-
-
-
-
-
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma b
-
-
-
-
-
-
-
Ocean Biomedical (AEHAU) Reports Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers
-
322,979 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

